JP2004536796A5 - - Google Patents

Info

Publication number

JP2004536796A5

JP2004536796A5 JP2002580947A JP2002580947A JP2004536796A5 JP 2004536796 A5 JP2004536796 A5 JP 2004536796A5 JP 2002580947 A JP2002580947 A JP 2002580947A JP 2002580947 A JP2002580947 A JP 2002580947A JP 2004536796 A5 JP2004536796 A5 JP 2004536796A5

Authority

JP

Japan

Prior art keywords

compound

group

substituted

alkyl

disease

Prior art date

2001-12-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 70
• 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims 14
• 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims 14
• 239000003814 drug Substances 0.000 claims 11
• 125000004404 heteroalkyl group Chemical group 0.000 claims 11
• 229940124597 therapeutic agent Drugs 0.000 claims 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims 9
• 125000001072 heteroaryl group Chemical group 0.000 claims 9
• 201000004624 Dermatitis Diseases 0.000 claims 8
• 125000003118 aryl group Chemical group 0.000 claims 8
• 125000004093 cyano group Chemical group *C#N 0.000 claims 8
• 229910052736 halogen Inorganic materials 0.000 claims 8
• 150000002367 halogens Chemical class 0.000 claims 8
• 230000001404 mediated effect Effects 0.000 claims 8
• 210000000056 organ Anatomy 0.000 claims 8
• -1 amidino, guanidino, ureido Chemical group 0.000 claims 7
• 125000001424 substituent group Chemical group 0.000 claims 7
• 206010028980 Neoplasm Diseases 0.000 claims 6
• 201000006417 multiple sclerosis Diseases 0.000 claims 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 6
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
• 201000004681 Psoriasis Diseases 0.000 claims 5
• 125000003545 alkoxy group Chemical group 0.000 claims 5
• 201000011510 cancer Diseases 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
• 125000004076 pyridyl group Chemical group 0.000 claims 5
• 201000001320 Atherosclerosis Diseases 0.000 claims 4
• 208000027496 Behcet disease Diseases 0.000 claims 4
• 208000009137 Behcet syndrome Diseases 0.000 claims 4
• 206010009900 Colitis ulcerative Diseases 0.000 claims 4
• 206010010741 Conjunctivitis Diseases 0.000 claims 4
• 208000011231 Crohn disease Diseases 0.000 claims 4
• 201000005569 Gout Diseases 0.000 claims 4
• 201000009906 Meningitis Diseases 0.000 claims 4
• 208000005141 Otitis Diseases 0.000 claims 4
• 206010039085 Rhinitis allergic Diseases 0.000 claims 4
• 206010040047 Sepsis Diseases 0.000 claims 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
• 201000006704 Ulcerative Colitis Diseases 0.000 claims 4
• 208000024780 Urticaria Diseases 0.000 claims 4
• 201000010105 allergic rhinitis Diseases 0.000 claims 4
• 208000006673 asthma Diseases 0.000 claims 4
• 208000010668 atopic eczema Diseases 0.000 claims 4
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
• 208000019258 ear infection Diseases 0.000 claims 4
• 206010014599 encephalitis Diseases 0.000 claims 4
• 208000006454 hepatitis Diseases 0.000 claims 4
• 231100000283 hepatitis Toxicity 0.000 claims 4
• 201000008383 nephritis Diseases 0.000 claims 4
• 230000004770 neurodegeneration Effects 0.000 claims 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims 4
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
• 201000000306 sarcoidosis Diseases 0.000 claims 4
• 201000009890 sinusitis Diseases 0.000 claims 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
• 208000035143 Bacterial infection Diseases 0.000 claims 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
• 229930105110 Cyclosporin A Natural products 0.000 claims 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 3
• 108010036949 Cyclosporine Proteins 0.000 claims 3
• 208000036142 Viral infection Diseases 0.000 claims 3
• 229960002170 azathioprine Drugs 0.000 claims 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 3
• 208000022362 bacterial infectious disease Diseases 0.000 claims 3
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
• 229960001265 ciclosporin Drugs 0.000 claims 3
• 229960004397 cyclophosphamide Drugs 0.000 claims 3
• 229910052739 hydrogen Inorganic materials 0.000 claims 3
• 210000004072 lung Anatomy 0.000 claims 3
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 3
• 229960005205 prednisolone Drugs 0.000 claims 3
• 229940002612 prodrug Drugs 0.000 claims 3
• 239000000651 prodrug Substances 0.000 claims 3
• 150000003839 salts Chemical class 0.000 claims 3
• 208000024891 symptom Diseases 0.000 claims 3
• 125000000335 thiazolyl group Chemical group 0.000 claims 3
• 125000001544 thienyl group Chemical group 0.000 claims 3
• 230000009385 viral infection Effects 0.000 claims 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims 2
• 108010008165 Etanercept Proteins 0.000 claims 2
• 108010044091 Globulins Proteins 0.000 claims 2
• 102000006395 Globulins Human genes 0.000 claims 2
• 108010005716 Interferon beta-1a Proteins 0.000 claims 2
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
• 125000004442 acylamino group Chemical group 0.000 claims 2
• 125000003282 alkyl amino group Chemical group 0.000 claims 2
• 125000002947 alkylene group Chemical group 0.000 claims 2
• 230000000781 anti-lymphocytic effect Effects 0.000 claims 2
• AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 2
• 229960005207 auranofin Drugs 0.000 claims 2
• 229940003504 avonex Drugs 0.000 claims 2
• 210000004027 cell Anatomy 0.000 claims 2
• 230000001684 chronic effect Effects 0.000 claims 2
• 229940073621 enbrel Drugs 0.000 claims 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
• 125000000623 heterocyclic group Chemical group 0.000 claims 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 2
• 229960004171 hydroxychloroquine Drugs 0.000 claims 2
• 125000002883 imidazolyl group Chemical group 0.000 claims 2
• 208000015181 infectious disease Diseases 0.000 claims 2
• 230000002757 inflammatory effect Effects 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 229960000485 methotrexate Drugs 0.000 claims 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 2
• 229940014456 mycophenolate Drugs 0.000 claims 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 2
• 230000000414 obstructive effect Effects 0.000 claims 2
• 229960001639 penicillamine Drugs 0.000 claims 2
• 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
• 229940116176 remicade Drugs 0.000 claims 2
• 229960001940 sulfasalazine Drugs 0.000 claims 2
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
• 229960001967 tacrolimus Drugs 0.000 claims 2
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
• 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
• XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 claims 1
• 241000894006 Bacteria Species 0.000 claims 1
• 229940126692 CXCR3 antagonist Drugs 0.000 claims 1
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
• 241000700605 Viruses Species 0.000 claims 1
• 125000000217 alkyl group Chemical group 0.000 claims 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
• 230000000340 anti-metabolite Effects 0.000 claims 1
• 230000001494 anti-thymocyte effect Effects 0.000 claims 1
• 229940100197 antimetabolite Drugs 0.000 claims 1
• 239000002256 antimetabolite Substances 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 229960001799 aurothioglucose Drugs 0.000 claims 1
• 210000001185 bone marrow Anatomy 0.000 claims 1
• 229940038717 copaxone Drugs 0.000 claims 1
• 229940111134 coxibs Drugs 0.000 claims 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
• 231100000433 cytotoxic Toxicity 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 230000001472 cytotoxic effect Effects 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 239000003862 glucocorticoid Substances 0.000 claims 1
• 150000002344 gold compounds Chemical class 0.000 claims 1
• 239000001257 hydrogen Substances 0.000 claims 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
• 229960003444 immunosuppressant agent Drugs 0.000 claims 1
• 230000001861 immunosuppressant effect Effects 0.000 claims 1
• 239000003018 immunosuppressive agent Substances 0.000 claims 1
• 210000003734 kidney Anatomy 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 210000000496 pancreas Anatomy 0.000 claims 1
• 210000004738 parenchymal cell Anatomy 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
• 229960002930 sirolimus Drugs 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1